Tuomas Jartti1, Matilda Aakula, Jonathan M Mansbach, Pedro A Piedra, Eija Bergroth, Petri Koponen, Juho E Kivistö, Ashley F Sullivan, Janice A Espinola, Sami Remes, Matti Korppi, Carlos A Camargo. 1. From the *Department of Pediatrics, Turku University Hospital, Turku, Finland; †Department of Medicine, Boston Children's Hospital, Boston, MA; ‡Departments of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX; §Department of Pediatrics, Kuopio University Hospital, Kuopio; ¶Department of Pediatrics, Tampere University Hospital, Tampere, Finland; and ‖Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA; **Allergy Unit, Tampere University Hospital, Tampere, Finland.
Abstract
OBJECTIVE: To determine whether hospital length-of-stay (LOS) for bronchiolitis is influenced by the causative virus: respiratory syncytial virus (RSV) or rhinovirus. METHODS: This prospective study was carried out in 3 university hospitals in Finland during 2 consecutive winter seasons. We enrolled consecutive children <2 years of age hospitalized with an attending physician's diagnosis of bronchiolitis. All enrolled children were included in the primary analysis. A parallel analysis was also conducted using a stricter definition for bronchiolitis (age <12 months and no history of wheeze). Polymerase chain reaction was used to test the nasopharyngeal aspirate samples for multiple respiratory pathogens. RESULTS: The median age of the 408 children was 8 months, 73% had no history of wheeze and their median hospital LOS was 2 days. 144 (35%) children had RSV only and 92 (23%) children rhinovirus only infections. Children with rhinovirus only had shorter duration of prehospital symptoms, higher disease severity score at entry and more often a history of wheezing (all P ≤ 0.001). Controlling for 7 demographic and clinical characteristics, those with rhinovirus only had shorter hospital LOS when compared with children with RSV only (adjusted odds ratio: 0.45; 95% confidence interval: 0.22-0.92; P = 0.03). The rhinovirus only finding was similar in the subset of 206 children with stricter diagnosis (adjusted odds ratio: 0.30; 0.06-1.49; P = 0.14). CONCLUSIONS: Hospital LOS is associated with rhinovirus etiology of bronchiolitis. Our data call attention to the importance of both RSV and rhinovirus testing in clinical research.
OBJECTIVE: To determine whether hospital length-of-stay (LOS) for bronchiolitis is influenced by the causative virus: respiratory syncytial virus (RSV) or rhinovirus. METHODS: This prospective study was carried out in 3 university hospitals in Finland during 2 consecutive winter seasons. We enrolled consecutive children <2 years of age hospitalized with an attending physician's diagnosis of bronchiolitis. All enrolled children were included in the primary analysis. A parallel analysis was also conducted using a stricter definition for bronchiolitis (age <12 months and no history of wheeze). Polymerase chain reaction was used to test the nasopharyngeal aspirate samples for multiple respiratory pathogens. RESULTS: The median age of the 408 children was 8 months, 73% had no history of wheeze and their median hospital LOS was 2 days. 144 (35%) children had RSV only and 92 (23%) childrenrhinovirus only infections. Children with rhinovirus only had shorter duration of prehospital symptoms, higher disease severity score at entry and more often a history of wheezing (all P ≤ 0.001). Controlling for 7 demographic and clinical characteristics, those with rhinovirus only had shorter hospital LOS when compared with children with RSV only (adjusted odds ratio: 0.45; 95% confidence interval: 0.22-0.92; P = 0.03). The rhinovirus only finding was similar in the subset of 206 children with stricter diagnosis (adjusted odds ratio: 0.30; 0.06-1.49; P = 0.14). CONCLUSIONS: Hospital LOS is associated with rhinovirus etiology of bronchiolitis. Our data call attention to the importance of both RSV and rhinovirus testing in clinical research.
Authors: Christopher J Stewart; Kohei Hasegawa; Matthew C Wong; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Janice A Espinola; Courtney N Tierney; Carlos A Camargo; Jonathan M Mansbach Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Orianne Dumas; Jonathan M Mansbach; Tuomas Jartti; Kohei Hasegawa; Ashley F Sullivan; Pedro A Piedra; Carlos A Camargo Journal: Thorax Date: 2016-06-23 Impact factor: 9.139
Authors: Jonathan M Mansbach; Kohei Hasegawa; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Courtney N Tierney; Janice A Espinola; Carlos A Camargo Journal: Clin Infect Dis Date: 2017-09-15 Impact factor: 9.079
Authors: Kohei Hasegawa; Tuomas Jartti; Jonathan M Mansbach; Federico R Laham; Alan M Jewell; Janice A Espinola; Pedro A Piedra; Carlos A Camargo Journal: J Infect Dis Date: 2014-11-25 Impact factor: 5.226
Authors: Jonathan M Mansbach; Sunday Clark; Stephen J Teach; James E Gern; Pedro A Piedra; Ashley F Sullivan; Janice A Espinola; Carlos A Camargo Journal: J Pediatr Date: 2016-02-11 Impact factor: 4.406
Authors: Miriam Cebey-López; Jethro Herberg; Jacobo Pardo-Seco; Alberto Gómez-Carballa; Nazareth Martinón-Torres; Antonio Salas; José María Martinón-Sánchez; Antonio Justicia; Irene Rivero-Calle; Edward Sumner; Colin Fink; Federico Martinón-Torres Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240
Authors: Janneke J H de Winter; Louis Bont; Berry Wilbrink; Cornelis K van der Ent; Henriette A Smit; Michiel L Houben Journal: Immun Inflamm Dis Date: 2015-08-27